J-Pharma advanced nanvuranlat (JPH-203) into a global Phase 3 study after aligning with the U.S. FDA, initiating the Beacon-BTC trial in biliary tract cancer. The move marks a step forward for the L-type amino acid transport 1 (LAT1) inhibition strategy in a tumor type with limited options. The company framed the Phase 3 progression as a direct follow-on to FDA alignment on the program, positioning the intravenous therapy for a confirmatory development path. Beacon-BTC is designed to test efficacy across a trial set relevant to clinical decision-making in biliary tract cancer. While specific endpoints and enrollment details were not provided in the excerpt, the decision to enter Phase 3 following regulatory alignment is a key milestone for sponsors building around transporter biology. For development teams watching metabolic and amino-acid targeting, the nanvuranlat update shows ongoing translation of selective transporter inhibition from earlier studies into late-stage confirmation.